http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
미세 골절 진달을 위한 초음파 C-scan의 활용 가능성
박원근,최민주,이원흠,이윤준,이헌주,강창익,박전홍 제주대학교 공과대학 첨단기술연구소 2001 尖端技術硏究所論文集 Vol.12 No.2
The study examines the medical potential of an ultrasonic C-scanning technique and for diagnosis of the fatigue induced micro-fractures of the bone. In general, it is not easy to detect the microfracture by a simple radiological technique. In the study, the microfractures were made on the tibia taken from pigs using a three point bending. Comparison was made between the ultrasonic C-scan images (25 MHz) and X-ray images of the bones with the micro-fractures, It was found that the micro-fractures invisible on the X-ray images were observed on the ultrasonic images. It is proposed further in-vitro and in-vivo studies making the ultrasonic C-scan technique clinically useful for the diagnosis of the fatigued induced micro-fractures of the bone which are not possible to detect by the conventional radiological method.
Hong, Seung-Heon,Kim, Hong-Joon,Cha, Dong-Seok,Lee, Ju-Young,Na, Ho-Jeong Kyung Hee Oriental Medicine Research Center 2007 Oriental pharmacy and experimental medicine Vol.7 No.3
In macrophages, nitric oxide (NO) is released as an inflammatory mediator and has been proposed to be an important modulator of many pathophysiological conditions including inflammation. In this study, we have examined the inhibition effects of NO production by 85% methanol extract of the flower of Pueraria thunbergiana (PF) in mouse macrophages. Extract of PF (1, 10, 100 ${\mu}g/ml$) inhibited NO production, inducible NO synthase and cyclooxygenase-2 expression in interferon-g and lipopolysaccharide-stimulated mouse peritoneal macrophages and it had no cytotoxicity. These data suggest that 85% methanol extract of PF might be useful in controlling macrophages mediated inflammatory disease.
Hong, Seong-Heon,Ban, Yeon Hee,Byun, Woong Sub,Kim, Donghwa,Jang, Yong-Joon,An, Joon Soo,Shin, Bora,Lee, Sang Kook,Shin, Jongheon,Yoon, Yeo Joon,Oh, Dong-Chan American Chemical Society and American Society of 2019 Journal of natural products Vol.82 No.4
<P>Chemical studies of gut bacteria of the carpenter ant <I>Camponotus kiusiuensis</I> led to the discovery of two new alkaloids, camporidines A and B (<B>1</B> and <B>2</B>), from <I>Streptomyces</I> sp. STA1. The structures of <B>1</B> and <B>2</B> were established as new polyketide alkaloids bearing a piperidine-cyclopentene-epoxide 6/5/3 tricyclic system based on NMR spectroscopic and mass spectrometric analysis. The relative configurations of the camporidines were determined by their <SUP>1</SUP>H-<SUP>1</SUP>H NOESY/ROESY and 1D NOE NMR correlations. The experimental ECD spectra of <B>1</B> and <B>2</B> were compared with their calculated ECD spectra to assign their absolute configurations. Camporidine A (<B>1</B>) displayed antimetastatic activity by suppression of cell invasion against the metastatic breast cancer cell line MDA-MB-231 and showed an anti-inflammatory effect by suppressing nitric oxide production induced by lipopolysaccharide. In addition, the putative biosynthetic gene cluster of the camporidines was identified, and the biosynthetic pathway of the camporidines was proposed based on bioinformatic analysis of the full genome of <I>Streptomyces</I> sp. STA1. Camporidines A and B (<B>1</B> and <B>2</B>) could be biosynthesized by a modular type I PKS containing an acyl transferase domain that accepts an unusual extender unit, which becomes the (C1′-C6′) hexyl side chain. The post-PKS modification enzymes were predicted to perform an amination and an oxidation along with spontaneous Schiff base formation and generate the unique piperidine-cyclopentene-epoxide 6/5/3 tricyclic framework.</P> [FIG OMISSION]</BR>
단위가축영양 : 육계에서 구멍갈파래의 항산화 및 면역조절 효과
홍준기 ( Joon Ki Hong ),봉미희 ( Mi Hee Bong ),박준철 ( Jun Cheol Park ),문홍길 ( Hong Kil Moon ),김동욱 ( Dong Wook Kim ),이상철 ( Sang Cheul Lee ),이준헌 ( Jun Heon Lee ) 한국동물자원과학회(구 한국축산학회) 2011 한국축산학회지 Vol.53 No.5
This study was conducted to test the efficacy of Ulva pertusa kjellman as immunomodulators under lipopolysaccharide(LPS) challenge in broilers by investigating their effects on serum superoxide dismutase(SOD) like ability, immunoglobulin concentration, and splenic cytokine mRNA expression. A total of ninety six1-d-old male broiler chicks(Ross 308) were divided into 4 treatment groups with 8 replicates of 3 birds in each group. NC(negative control, no immune substances), PC(positive control, β-glucan 25 ppm), Ulva P(Ulva pertusa kjellman Powder 3%), and Ulva E(Extract form Ulva pertusa kjellman 0.3%) were added in feed with respective substance. Heparinized venous blood and spleens were collected from five birds per dietary treatment at 5 wk of age. The SOD like activities in Ulva P and Ulva E were significantly increased in comparison with other groups(P<0.05). The immunoglobulin M content was lower in the Ulva E than other groups(P<0.05). Expression patterns of splenic cytokine mRNA in the IL-1β, IL-2 and IL-6 were similar. Expression rate of IL-1β, IL-2 and IL-6 in Ulva pertusa kjellman(Ulva P, Ulva E) were decreased(P<0.05) in comparison to other groups. Expression rate of IL-1β, IL-2 and IL-6 were significantly lower in groups treated with Ulva E than Ulva P. In conclusion, dietary supplementation of Ulva pertusa kjellman improved SOD like activity and affect immune system by inhibiting inflammatory response in broiler chicks. In addition, it is more effective to use Ulva pertusa kjellman extract than powder for immunomodulatory function. These results suggest the possibility that Ulva pertusa kjellman could be used as the immunomodulator for inflammatory response in broiler chicks.
홍삼 부산물이 스트레스에 대한 산란계 생체반응에 미치는 영향
홍준기(Joon Ki Hong),봉미희(Mi Hee Bong),박준철(Jun Cheol Park),문홍길(Hong Kil Moon),이상철(Sang Cheul Lee),이준헌(Jun Heon Lee),황성구(Seong Gu Hwang) 韓國家禽學會 2012 韓國家禽學會誌 Vol.39 No.1
This study was conducted to determine the possible use of Red Ginseng marc as stress inhibiter in thermal stress (temperature humidity index 86) and lipopolysaccharide (LPS)-exposed laying hens by investigating their effects on laying performance, blood biochemical parameters, immunoglobulin concentration and serum superoxide dismutase (SOD) like ability. A total of forty-five 52-wk-old laying hens (ISA Brown) were divided into 3 treatment groups with 5 replicates of 3 birds in each group. NC (negative control, no immune substances), PC (positive control, β-glucan 25 ppm) and RGM (Red Ginseng Marc 3%) were added in feed with respective substance. Egg production in RGM was significantly increased in comparison with NC groups for 8 weeks (P<0.05). On blood biochemical parameters, effects of ambient temperature is definite by showing significant difference in aspartate aminotransferase and others (P<0.05), but RGM both before and after thermal stimulation have no significant difference in comparison with other groups. And for 3 weeks after thermal stimulation, laying performance was also not significantly different among treatments. Immunoglobulin M content and SOD like activities after challenge with LPS were higher in the RGM and PC than NC (P<0.05). In conclusion, although ineffective as inhibiter in thermal stress, dietary supplementation of Red Ginseng marc improved SOD like activity and immune system by regulating immunoglobulin content in laying hens. These findings have laid the foundation for future studies of immunomodulation in laying hens fed Red Ginseng Marc and of evaluation of heat stress inhibitor.
Hong, Soon Jun,Jeong, Han Saem,Ahn, Jeong Cheon,Cha, Dong-Hun,Won, Kyung Heon,Kim, Weon,Cho, Sang Kyoon,Kim, Seok-Yeon,Yoo, Byung-Su,Sung, Ki Chul,Rha, Seung-Woon,Shin, Joon-Han,Han, Kyoo Rok,Chung, W Elsevier 2018 Clinical therapeutics Vol.40 No.2
<P><B>Abstract</B></P> <P><B>Purpose</B></P> <P>Combination therapy with ezetimibe and statins is recommended in cases of statin intolerance or insufficiency. The objective of this study was to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus those of rosuvastatin monotherapy in patients with hypercholesterolemia.</P> <P><B>Methods</B></P> <P>I-ROSETTE (Ildong ROSuvastatin & ezETimibe for hypercholesTElolemia) was an 8-week, double-blind, multicenter, Phase III randomized controlled trial conducted at 20 hospitals in the Republic of Korea. Patients with hypercholesterolemia who required medical treatment according to National Cholesterol Education Program Adult Treatment Panel III guidelines were eligible for participation in the study. Patients were randomly assigned to receive ezetimibe 10 mg/rosuvastatin 20 mg, ezetimibe 10 mg/rosuvastatin 10 mg, ezetimibe 10 mg/rosuvastatin 5 mg, rosuvastatin 20 mg, rosuvastatin 10 mg, or rosuvastatin 5 mg in a 1:1:1:1:1:1 ratio. The primary end point was the difference in the mean percent change from baseline in LDL-C level after 8 weeks of treatment between the ezetimibe/rosuvastatin and rosuvastatin treatment groups. All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs.</P> <P><B>Findings</B></P> <P>Of 396 patients, 389 with efficacy data were analyzed. Baseline characteristics among 6 groups were similar. After 8 weeks of double-blind treatment, the percent changes in adjusted mean LDL-C levels at week 8 compared with baseline values were –57.0% (2.1%) and –44.4% (2.1%) in the total ezetimibe/rosuvastatin and total rosuvastatin groups, respectively (<I>P</I> < 0.001). The LDL-C–lowering efficacy of each of the ezetimibe/rosuvastatin combinations was superior to that of each of the respective doses of rosuvastatin. The mean percent change in LDL-C level in all ezetimibe/rosuvastatin combination groups was >50%. The number of patients who achieved target LDL-C levels at week 8 was significantly greater in the ezetimibe/rosuvastatin group (180 [92.3%] of 195 patients) than in the rosuvastatin monotherapy group (155 [79.9%] of 194 patients) (<I>P</I> < 0.001). There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups.</P> <P><B>Implications</B></P> <P>Fixed-dose combinations of ezetimibe/rosuvastatin significantly improved lipid profiles in patients with hypercholesterolemia compared with rosuvastatin monotherapy. All groups treated with rosuvastatin and ezetimibe reported a decrease in mean LDL-C level >50%. The safety and tolerability of ezetimibe/rosuvastatin therapy were comparable with those of rosuvastatin monotherapy. ClinicalTrials.gov identifier: NCT02749994.</P>